Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa (L-
dopa) therapy for Parkinson's disease (PD). L-dopa-induced dyskinesia (LID) are ultimately …

Dopaminergic medications used in the treatment of patients with Parkinson's disease are
associated with motor and non-motor behavioural side-effects, such as dyskinesias and …

Tau is a developmentally regulated axonal protein that stabilizes and bundles microtubules
(MTs). Its hyperphosphorylation is thought to cause detachment from MTs and subsequent …

High rates of relapse to drug use during abstinence is a defining feature of human drug
addiction. This clinical scenario has been studied at the preclinical level using different …

Lysosomal impairment causes lysosomal storage disorders (LSD) and is involved in
pathogenesis of neurodegenerative diseases, notably Parkinson disease (PD). Strategies …

Whether fear attenuation is mediated by inhibition of the original memory trace of fear with a
new memory trace of safety or by updating of the original fear trace toward safety has been a …

Parkinson's disease is characterized by the progressive loss of midbrain dopamine neurons.
Dopamine replacement therapy with levodopa alleviates parkinsonian motor symptoms but …

Actions of the neurotransmitter dopamine in the brain are mediated by dopamine receptors
that belong to the superfamily of G protein-coupled receptors (GPCRs). Mammals have five …

We recently developed a rat model of incubation of methamphetamine craving after choice-
based voluntary abstinence. Here, we studied the role of dorsolateral striatum (DLS) and …

Loss of control over drinking is a key deficit in alcoholism causally associated with
malfunction of the medial prefrontal cortex (mPFC), but underlying molecular and cellular …